Results 151 to 160 of about 22,351 (243)

Investigation of fingolimod-induced lymphocyte sequestration on inflammatory response and neurological damages after cardiac arrest

Intensive Care Medicine Experimental
Background A sepsis-like syndrome is known to occur after cardiac arrest, leading to cerebral infiltration by white blood cells (WBC). We hypothesized that pharmacological sequestration of WBC, and more specifically lymphocytes within lymphoid tissues ...
Yara Abi Zeid Daou, Fanny Lidouren, Antoine Bois, Naoto Watanabe, Ali Jendoubi, Estelle Faucher, Mathieu Surenaud, Sophie Chateau-Joubert, Sophie Hue, Bijan Ghaleh, Matthias Kohlhauer, Renaud Tissier   +11 more
doaj   +1 more source

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients

, 2016
Objective: Many JC virus antibody-positive relapsing-remitting multiple sclerosis (RRMS) patients who are stable on natalizumab switch to other therapies to avoid progressive multifocal leukoencephalopathy.Methods: We compared outcomes for all RRMS ...
Frisell, T., Frisell, Thomas, Novakova, Lenka,, Thomas Frisell, Jan Lycke, Novakova, Lenka, Björck, Anna, Peter Alping, Malmeström, Clas, Salzer, Jonatan,, Svenningsson, Anders,, Lycke, Jan, Protik Islam‐Jakobsson, Axelsson, Markus, Axelsson, Markus,, Piehl, F., Islam-Jakobsson, Protik,, Bjorck, A., Anna Björck, Fredrik Piehl, Alping, P., Malmeström, Clas,, Salzer, J., Clas Malmeström, Anders Svenningsson, Piehl, Fredrik, Jonatan Salzer, Alping, Peter, Svenningsson, A., Katharina Fink, Lycke, Jan,, Fink, K., Lenka Novakova, Fink, Katharina, Markus Axelsson, Islam-Jakobsson, P.   +35 more
core   +1 more source

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

New England Journal of Medicine, 2010
Jeffrey A. Cohen, F. Barkhof, G. Comi, H. Hartung, B. Khatri, X. Montalban, J. Pelletier, R. Capra, P. Gallo, G. Izquierdo, K. Tiel‐Wilck, Ana de Vera, James Jin, T. Stites, Stacy Wu, S. Aradhye, L. Kappos   +16 more
semanticscholar   +1 more source

Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis

, 2018
Objective: This propensity score–matched analysis from MSBase compared the effectiveness of cladribine with interferon β, fingolimod or natalizumab.
Horakova D., Sola P., Spelman T., Havrdova E., Slee M., Girard M., Shaw C., Solaro C., Hupperts R., Grand'Maison F., Prevost J., Grammond P., Kalincik T., Lugaresi A., Kermode A., Terzi M., Fabis-Pedrini M., Jokubaitis V., Hodgkinson S., Lechner-Scott J., Trojano M., Ferraro D., Duquette P., McCombe P., Barnett M., Butzkueven H., Butler E., Prat A.   +27 more
core   +1 more source

Fingolimod increases cellular resistance to HIV-1 infection and limits viral reservoir size in peripheral CD4+ T-cells. [PDF]

PLoS Pathog
Moraga E, Climent N, Sánchez-Molina A, Vicens-Artés S, Maleno MJ, Valero López G, Galera Peñaranda C, Ambrosioni J, Miró JM, Mallolas J, Albendín-Iglesias H, Alcamí J, Sánchez-Palomino S.   +12 more
europepmc   +1 more source

Repurposing Fingolimod as an Antibacterial and Antibiofilm Agent against Carbapenem-Resistant <i>Acinetobacter baumannii</i>. [PDF]

ACS Omega
Jin HW, Bae JH, Youn HS, Eom YB.
europepmc   +1 more source

Chronic HPV associated lesions associated with Fingolimod use

, 2018
Background: Fingolimod is a an effective immunosuppressive therapy used to reduce relapse rates in relapsing remitting MS. Fingolimod is a sphingosine 1-phosphate (S1-P) analogue and has antagonistic effects on S1-P receptors causing in S1-P receptor ...
Kermode, A.G., Triplett, J.D.
core  

Do apelin and ghrelin play a role in multiple sclerosis? The analysis of patients treated with immunomodulatory therapies. [PDF]

Front Immunol
Adamczyk B, Morawiec N, Rakoca M, Sowa A, Sawa K, Adamczyk-Sowa M.   +5 more
europepmc   +1 more source

LncRNA AFAP1-AS1 mediates therapy-dependent expression of CCL5, CXCL10 and MMP9 in multiple sclerosis. [PDF]

Biochem Biophys Rep
Hegazy LN, Elkhodiry AA, Rashad MH, Moustafa RR, El Tayebi HM.   +4 more
europepmc   +1 more source

Therapeutic Potential of Fingolimod and Dimethyl Fumarate in Preclinical Pancreatic Cancer Models. [PDF]

Oncol Res
Gousseau P, Genest L, Froget G, Rupp T.
europepmc   +1 more source